Vadimezan
- Generic Name
- Vadimezan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14O4
- CAS Number
- 117570-53-3
- Unique Ingredient Identifier
- 0829J8133H
- Indication
Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01285453
- Locations
- 🇯🇵
Novartis Investigative Site, Osaka, Japan
Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 17
- Registration Number
- NCT01057342
- Locations
- 🇨ðŸ‡
Inselspital Bern, Bern, Switzerland
🇨ðŸ‡Spitalzentrum Biel, Biel, Switzerland
🇨ðŸ‡Saint Claraspital AG, Basel, Switzerland
Study of DMXAA (Now Known as ASA404) in Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2009-03-18
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 63
- Registration Number
- NCT00863733
Phase I Safety Study of DMXAA in Refractory Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2009-03-05
- Lead Sponsor
- Antisoma Research
- Target Recruit Count
- 15
- Registration Number
- NCT00856336
Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- University of Glasgow
- Target Recruit Count
- 3
- Registration Number
- NCT00003697
- Locations
- 🇬🇧
Mount Vernon Hospital, Northwood, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath